{"doi":"10.1056/nejmoa1505067","title":"Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer","abstract":null,"journal":"New England Journal of Medicine","year":2016,"id":602585,"datarank":0.8862124407253398,"base_score":5.908082938168931,"endowment":5.908082938168931,"self_citation_contribution":0.8862124407253398,"citation_network_contribution":0.0,"self_endowment_contribution":0.8862124407253398,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":367,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":50711,"name":"Mark F. Brady","orcid":"0000-0001-6700-2981","position":1,"is_corresponding":false},{"id":241546,"name":"Richard T. Penson","orcid":"0000-0002-8091-8588","position":2,"is_corresponding":false},{"id":830958,"name":"Helen Huang","orcid":"0000-0001-5301-3890","position":3,"is_corresponding":false},{"id":647757,"name":"Michael J. Birrer","orcid":"0000-0001-6464-4225","position":4,"is_corresponding":false},{"id":79902,"name":"Joan L. Walker","orcid":"0000-0002-5034-4309","position":5,"is_corresponding":false},{"id":1545446,"name":"Paul A. DiSilvestro","orcid":null,"position":6,"is_corresponding":false},{"id":1545447,"name":"Stephen C. Rubin","orcid":null,"position":7,"is_corresponding":false},{"id":633134,"name":"Lainie P. Martin","orcid":"0000-0002-3802-015X","position":8,"is_corresponding":false},{"id":525634,"name":"Susan A. Davidson","orcid":"0000-0003-3436-6513","position":9,"is_corresponding":false},{"id":256633,"name":"Warner K. Huh","orcid":"0000-0003-2881-9846","position":10,"is_corresponding":false},{"id":258149,"name":"David M. O’Malley","orcid":"0000-0002-2828-0177","position":11,"is_corresponding":false},{"id":1545451,"name":"Matthew P. Boente","orcid":null,"position":12,"is_corresponding":false},{"id":271846,"name":"Helen Michael","orcid":"0000-0002-8326-0806","position":13,"is_corresponding":false},{"id":258132,"name":"Bradley J. Monk","orcid":"0000-0001-6985-0159","position":14,"is_corresponding":false},{"id":525633,"name":"John K. Chan","orcid":"0000-0003-3379-6829","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer","abstract":"<h4>Background</h4>A dose-dense weekly schedule of paclitaxel (resulting in a greater frequency of drug delivery) plus carboplatin every 3 weeks or the addition of bevacizumab to paclitaxel and carboplatin administered every 3 weeks has shown efficacy in ovarian cancer. We proposed to determine whether dose-dense weekly paclitaxel and carboplatin would prolong progression-free survival as compared with paclitaxel and carboplatin administered every 3 weeks among patients receiving and those not receiving bevacizumab.<h4>Methods</h4>We prospectively stratified patients according to whether they elected to receive bevacizumab and then randomly assigned them to receive either paclitaxel, administered intravenously at a dose of 175 mg per square meter of body-surface area every 3 weeks, plus carboplatin (dose equivalent to an area under the curve [AUC] of 6) for six cycles or paclitaxel, administered weekly at a dose of 80 mg per square meter, plus carboplatin (AUC, 6) for six cycles. The primary end point was progression-free survival.<h4>Results</h4>A total of 692 patients were enrolled, 84% of whom opted to receive bevacizumab. In the intention-to-treat analysis, weekly paclitaxel was not associated with longer progression-free survival than paclitaxel administered every 3 weeks (14.7 months and 14.0 months, respectively; hazard ratio for disease progression or death, 0.89; 95% confidence interval [CI], 0.74 to 1.06; P=0.18). Among patients who did not receive bevacizumab, weekly paclitaxel was associated with progression-free survival that was 3.9 months longer than that observed with paclitaxel administered every 3 weeks (14.2 vs. 10.3 months; hazard ratio, 0.62; 95% CI, 0.40 to 0.95; P=0.03). However, among patients who received bevacizumab, weekly paclitaxel did not significantly prolong progression-free survival, as compared with paclitaxel administered every 3 weeks (14.9 months and 14.7 months, respectively; hazard ratio, 0.99; 95% CI, 0.83 to 1.20; P=0.60). A test for interaction that assessed homogeneity of the treatment effect showed a significant difference between treatment with bevacizumab and without bevacizumab (P=0.047). Patients who received weekly paclitaxel had a higher rate of grade 3 or 4 anemia than did those who received paclitaxel every 3 weeks (36% vs. 16%), as well as a higher rate of grade 2 to 4 sensory neuropathy (26% vs. 18%); however, they had a lower rate of grade 3 or 4 neutropenia (72% vs. 83%).<h4>Conclusions</h4>Overall, weekly paclitaxel, as compared with paclitaxel administered every 3 weeks, did not prolong progression-free survival among patients with ovarian cancer. (Funded by the National Cancer Institute and Genentech; GOG-0262 ClinicalTrials.gov number, NCT01167712.).","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"26933849","pmcid":"PMC5081077","openalex_id":null,"authors":[],"funders":[{"funder_name":"NCI NIH HHS","grant_id":"U10 CA180850","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U10 CA180822","title":null},{"funder_name":"NCI NIH HHS","grant_id":"UG1 CA189867","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U10 CA101165","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U10 CA180868","title":null},{"funder_name":"NCI NIH HHS","grant_id":"P30 CA006927","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U10 CA037517","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U10 CA180855","title":null},{"funder_name":"NCI NIH HHS","grant_id":"U10 CA027469","title":null}],"total_grants":9,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":null,"license":null,"oa_locations":[{"url":"http://www.nejm.org/doi/pdf/10.1056/NEJMoa1505067","host_type":"publisher"}],"fields_of_study":[],"mesh_terms":["Humans","Ovarian Neoplasms","Paclitaxel","Carboplatin","Antineoplastic Combined Chemotherapy Protocols","Disease-Free Survival","Infusions, Intravenous","Drug Administration Schedule","Middle Aged","Female","Intention to Treat Analysis","Bevacizumab"],"keywords":[],"sdg_mappings":[],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"nct"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-29T19:46:38.920115Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}